A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 7, 2012, Pages 1066-1077

  Sigal, Bronislava M ^a   Munoz, Diego F ^a   Kurian, Allison W ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; GENE MUTATION; GENETIC SCREENING; HETEROZYGOTE; LIFE EXPECTANCY; METASTASIS; MONTE CARLO METHOD; OVARY CANCER; PRIORITY JOURNAL; PROPHYLACTIC MASTECTOMY; PROPHYLACTIC OOPHORECTOMY; RISK ASSESSMENT; RISK REDUCTION; SIMULATION; TUMOR VOLUME;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; FEMALE; HETEROZYGOTE; HUMANS; LIFE EXPECTANCY; MASTECTOMY; MIDDLE AGED; MODELS, STATISTICAL; OVARIAN NEOPLASMS; OVARIECTOMY;

EID: 84863588455     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0149     Document Type: Article

References (43)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30. (Pubitemid 36530000)
2. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33. (Pubitemid 46706879)
3. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. V. 1.2011. Fort Washington, PA: NCCN. [cited 2011 Jul]. Available from: http://www.nccn.org.
4. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 2007;298:2869-76.
5. Tengs TO, Winer EP, Paddock S, Aguilar-Chavez O, Berry DA. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998;18:365-75. (Pubitemid 28465276)
6. National Comprehensive Cancer Network Guidelines for genetic/familial high-risk assessment: breast and ovarian. Fort Washington, PA: NCCN. [cited 2011 Jul]. Available from: http://www.nccn.org/professionals/physician-gls/PDF/ genetics-screening.pdf.
7. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-76.
8. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
9. National Comprehensive Cancer Network. Breast cancer screening and diagnosis V.1.20011. Fort Washington, PA: NCCN. [cited 2011 Jul]. Available from: http://www.nccn.org.
10. Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, et al. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006;295:2374-84. (Pubitemid 43788105)
11. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35. (Pubitemid 41115389)
12. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-62. (Pubitemid 41095038)
13. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185-92.
14. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15. (Pubitemid 34755668)
15. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22. (Pubitemid 34755669)
16. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-6. (Pubitemid 46291812)
17. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004;10:2029-34. (Pubitemid 38375563)
18. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-83. (Pubitemid 47517552)
19. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-9.
20. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ III. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-8. (Pubitemid 44464065)
21. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10. (Pubitemid 17052498)
22. Melton LJ III, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-5. (Pubitemid 37294974)
23. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010;28:222-31.
24. Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol 2012;30:497-506.
25. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92. (Pubitemid 41549890)
26. Plevritis SK, Sigal BM, Salzman P, Rosenberg J, Glynn P. A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 2006;86-95.
27. Plevritis SK, Salzman P, Sigal BM, Glynn PW. A natural history model of stage progression applied to breast cancer. Stat Med 2007;26:581-95. (Pubitemid 46139540)
28. Chappuis PO, Nethercot V, Foulkes WD. Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 2000;18:287-95. (Pubitemid 30253021)
29. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI andmammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
30. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-78. (Pubitemid 40744657)
31. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-25. (Pubitemid 39223222)
32. Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, et al. Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Res 2010;12:R12.
33. Evans DG, Young K, Bulman M, Shenton A, Wallace A, Lalloo F. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet 2008;73:338-45. (Pubitemid 351386993)
34. Lakhani SR, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-81. (Pubitemid 38445709)
35. Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004;23:29-34. (Pubitemid 38018234)
36. Berkeley Mortality Database. [cited 2008 Aug 4]. Available from: http://www.demog.berkeley.edu/~bmd/States/ssa/life.tables/ufgen.lt.1x1%5D.
37. CDC/NCHS, National Vital Statistics System, Worktable 292R. Death rates for 358 selected causes by 5-year age groups, race, and sex: United States, 1999-2004. [cited 2008 Aug 4]. Available from: http://www.cdc.gov/nchs/data/dvs/ mortfinal2004-worktable292r.pdf.
38. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 2005;106:219-26. (Pubitemid 41023257)
39. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006;144:397-406. (Pubitemid 46768161)
40. Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol 1998;16:979-85. (Pubitemid 28108730)
41. Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 2011;125:837-47.
42. Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, et al. Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis. Cancer 2012;118:2021-30.
43. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71. (Pubitemid 27208615)